Klubo-Gwiezdzinska J, et al. - Diabetes refractory to massive doses of insulin, severe hypercatabolism, hyperandrogenism, and a high mortality rate characterize type B insulin resistance due to autoantibodies against the insulin receptor, so researchers assessed combined immunosuppressive therapy for its effectiveness in the management of this extreme form of diabetes. The results of this prospective cohort study indicate that combined immunosuppressive therapy has changed the outcomes of this disease, from a 54% mortality rate to making it a curable form of diabetes and, as such, should be advised for those with type B insulin resistance.